Phase 3 trials are ongoing for pelacarsen and olpasiran, with outcome data expected in 2025 and 2026, respectively. 128, 131 An additional small interfering RNA, lepodisiran, is currently under ...

Lp(a) only modestly improved prediction when added to risk estimates, but it still can be used to personalize care.

Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel.

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis.

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs like MariTide and olpasiran to offset losses. Recent financials show solid revenue growth and improved ...

Amgen’s Imdelltra, a bispecific T-cell engager (BiTE) that targets Delta-like canonical Notch ligand 3 (DLL3) and cluster of differentiation 3 (CD3) receptors, received US Food and Drug Administration ...

Amgen’s Imdelltra, a delta-like ligand 3 targeting Bispecific T-cell Engager (BiTE) therapy, was approved by the FDA in 2024 for pre-treated extensive-stage small cell lung cancer ...

Amgen took the lead in this space in 2022 when it reported placebo-adjusted lipoprotein(a) reductions of 95% in its phase 2 trial that suggested its interfering RNA treatment, olpasiran, had an ...